| Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 … S Willier, E Butt, TGP Grunewald Biology of the Cell 105 (8), 317-333, 2013 | 162 | 2013 |
| Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice … F Blaeschke, D Stenger, T Kaeuferle, S Willier, R Lotfi, AD Kaiser, ... Cancer Immunology, Immunotherapy 67, 1053-1066, 2018 | 147 | 2018 |
| Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation T Kaeuferle, R Krauss, F Blaeschke, S Willier, T Feuchtinger Journal of hematology & oncology 12, 1-10, 2019 | 132 | 2019 |
| Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR D Stenger, TA Stief, T Kaeuferle, S Willier, F Rataj, K Schober, B Vick, ... Blood, The Journal of the American Society of Hematology 136 (12), 1407-1418, 2020 | 109 | 2020 |
| The Zyxin‐related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth TGP Grunewald, S Willier, D Janik, R Unland, C Reiss, OP da Costa, ... Biology of the Cell 105 (11), 535-547, 2013 | 54 | 2013 |
| CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy S Willier, P Rothämel, M Hastreiter, J Wilhelm, D Stenger, F Blaeschke, ... Blood, The Journal of the American Society of Hematology 137 (8), 1037-1049, 2021 | 52 | 2021 |
| Defining the role of TRIP6 in cell physiology and cancer S Willier, E Butt, GHS Richter, S Burdach, TGP Grunewald Biology of the Cell 103 (12), 573-591, 2011 | 48 | 2011 |
| Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients F Blaeschke, S Willier, D Stenger, M Lepenies, MA Horstmann, ... Leukemia 34 (10), 2607-2620, 2020 | 34 | 2020 |
| Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy F Blaeschke, MC Paul, MU Schuhmann, A Rabsteyn, C Schroeder, ... Cytotherapy 21 (9), 973-986, 2019 | 29 | 2019 |
| CRISPR-Cas9-mediated glucocorticoid resistance in virus-specific T cells for adoptive T cell therapy posttransplantation T Kaeuferle, L Deisenberger, L Jablonowski, TA Stief, F Blaeschke, ... Molecular Therapy 28 (9), 1965-1973, 2020 | 23 | 2020 |
| Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins F Blaeschke, D Stenger, A Apfelbeck, BL Cadilha, MR Benmebarek, ... Blood Cancer Journal 11 (6), 108, 2021 | 19 | 2021 |
| Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly … S Willier, KM Cabanillas Stanchi, M von Have, V Binder, F Blaeschke, ... BMC cancer 19, 1-11, 2019 | 13 | 2019 |
| Design and evaluation of TIM-3-CD28 checkpoint fusion proteins to improve anti-CD19 CAR T-cell function F Blaeschke, E Ortner, D Stenger, J Mahdawi, A Apfelbeck, N Habjan, ... Frontiers in Immunology 13, 845499, 2022 | 12 | 2022 |
| Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells S Willier, J Raedler, F Blaeschke, D Stenger, MP Escudero, F Jurgeleit, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 9 | 2020 |
| Genome‐wide off‐target analyses of CRISPR/Cas9‐mediated T‐cell receptor engineering in primary human T cells T Kaeuferle, TA Stief, S Canzar, NN Kutlu, S Willier, D Stenger, ... Clinical & Translational Immunology 11 (1), e1372, 2022 | 6 | 2022 |
| Endogenous TCR Promotes D Stenger, TA Stief, T Kaeuferle, S Willier, F Rataj, K Schober Vivo, 2020 | 5 | 2020 |
| Generation of full-length circular RNA libraries for Oxford Nanopore long-read sequencing S Fuchs, L Babin, E Andraos, C Bessiere, S Willier, JH Schulte, C Gaspin, ... PloS one 17 (9), e0273253, 2022 | 4 | 2022 |
| Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections TA Stief, T Kaeuferle, TR Müller, M Döring, LM Jablonowski, K Schober, ... Molecular Therapy 30 (1), 198-208, 2022 | 4 | 2022 |
| Identification of predictive markers of severe and prolonged neutropenia after CD19-specific CAR T-cell treatment in patients with relapsed/refractory B-cell malignancies K Rejeski, C Berger, L Jentzsch, S Willier, V Blumenberg, V Buecklein, ... Blood 136, 41-42, 2020 | 4 | 2020 |
| Antiemetic Prophylaxis with Fosaprepitant and 5-HT3-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation KM Cabanillas Stanchi, S Willier, J Vek, P Schlegel, M Queudeville, ... Drug Design, Development and Therapy, 3915-3927, 2020 | 3 | 2020 |
Dana StengerLMUVerified email at med.uni-muenchen.de
